COMMUNIQUÉS West-GlobeNewswire

WellRithms Featured for Fourth Consecutive Year on Portland Business Journal List of Fastest-Growing Private Companies
16/09/2024
PORTLAND, Ore., Sept. 16, 2024 (GLOBE NEWSWIRE) -- WellRithms , the industry leading payment integrity firm, announces the Company’s fourth consecutive year of recognition from the Portland Business Journal as one of [...]
Thought Leadership & Innovation Foundation Announces Gala to Initiate Development of Patient Portal for Age-Related Macular Degeneration
16/09/2024
Howard Fine, MD Delivers Keynote MCLEAN, Va., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and [...]
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
16/09/2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]
Novo Nordisk A/S - share repurchase programme
16/09/2024
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
16/09/2024
Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therapy Equillium targeting initiation of Phase 1 study investigating EQ302 in 2H 2025 [...]
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16/09/2024
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
London Man Grateful to Doctors Who Treated Rare Flesh-Eating Disease, Pledges $25,000
16/09/2024
LONDON, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) -- While on vacation in Napa Valley last year, Colleen DeJager’s world imploded when she received a startling call from back home—her husband Rick was admitted to London [...]
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
16/09/2024
Expands available market to include over 200 children’s hospitals in the United States LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid [...]
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
16/09/2024
Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth [...]
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16/09/2024
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ® (cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic [...]
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
16/09/2024
Les données ont démontré une réduction significative, tant sur le plan statistique que sur le plan clinique, du risque de progression de la maladie ou de décès avec Cabometyx ® (cabozantinib) par rapport au placebo dans [...]
NeuroStar® Releases Software Upgrades to Elevate Patient Care
16/09/2024
Upgrades improve communication, streamline data management, and strengthen security MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]
Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients
16/09/2024
In the US pivotal trial, WRAPSODY achieved 89.8% target lesion primary patency at 6 months SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare [...]
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
16/09/2024
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical [...]
BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research
16/09/2024
Partnership increases physician and patient participation in clinical trials GRAND RAPIDS, Mich. and SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BAMF Health, a world leader in molecular imaging and Theranostics [...]
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16/09/2024
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for [...]
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
16/09/2024
September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant Funds to Advance Development of Phase 3 Asset Biodexa Pharmaceuticals [...]
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16/09/2024
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
15/09/2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1 Injected and non- [...]

Pages